A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation.
10.19746/j.cnki.issn.1009-2137.2022.01.047
- Author:
Juan CHEN
1
;
Li-Li YUAN
2
;
Xian ZHANG
3
;
Jia-Li QIAO
1
;
Qing-Xue YIN
1
;
Yue-Mei ZHANG
1
;
Xue-Lian YANG
1
;
Xing-Yu CAO
4
Author Information
1. Blood Cell Room, Hebei Yanda Lu Daopei Hospital, Langfang 065201, Hebei Province, China.
2. Department of Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, Langfang 065201, Hebei Province, China.
3. Department of Hematology, Hebei Yanda Lu Daopei Hospital, Langfang 065201, Hebei Province, China.
4. Department of Transplantation, Hebei Yanda Lu Daopei Hospital, Langfang 065201, Hebei Province, China,E-mail: caoxingyu2020@sina.com.
- Publication Type:Journal Article
- Keywords:
allogenic stem cell transplantation;
granulocyte colony-stimulating factor;
hematopoietic stem cell mobilization;
plerixafor
- MeSH:
Antigens, CD34;
Benzylamines;
Cyclams;
Granulocyte Colony-Stimulating Factor;
Hematopoietic Stem Cell Mobilization;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Heterocyclic Compounds;
Humans;
Peripheral Blood Stem Cell Transplantation;
Retrospective Studies
- From:
Journal of Experimental Hematology
2022;30(1):286-291
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the effect and safety of G-CSF combined with Plerixafor on the mobilization of peripheral blood hematopoietic stem cells from healthy related donors of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODS:It was analyzed retrospectively that the data of peripheral blood hematopoietic stem cells from 33 (observation group) related donors mobilized by G-CSF plus Plerixafor in Hebei Yanda Lu Daopei Hospital from April 2019 to April 2021. Bone marrow and peripheral blood hematopoietic stem cells (PBSCs) of these donors were respectively collected on the fourth and fifth day of G-CSF-induced mobilization. Following the administration of Plerixafor on the night of the fifth day, PBSCs were collected on the sixth day once again. 46 donors using "G-CSF only" mobilization method in the same period were randomly selected as the control and respectively analyzed the differences of CD34+ cell counts on the fifth and the sixth day in two groups. And the donors' adverse reaction to Plerixafor in the form of questionnaire was also observed. Then it was compared that the patients who underwent allo-HSCT in "G-CSF+Plerixafor" group and "G-CSF only" group in terms of acute GVHD at grade I-IV or III-IV, CMV reactivation and EBV reactivation.
RESULTS:CD34+ cells count (M±Q) among PBSCs collected on the fifth and the sixth day in the observation group were (1.71±1.02)×106/kg and (4.23±2.33)×106/kg, respectively. CD34+ cell counts on the sixth day was significantly higher than that of the fifth day (P<0.001); While the counterparts in the control group were (2.47±1.60)×106/kg and (1.87±1.37)×106/kg, respectively. By statistical analysis, CD34+ cell counts on the sixth day was significantly less than that of the fifth day (P<0.001). The adverse reaction to Plerixafor for the donors in the study were all grade 1 or 2 (mild or moderate) according to CTCAE 5.0 and disappeared in a short time. The patients who underwent allo-HSCT in the "G-CSF+Plerixafor" group and "G-CSF only" group were not statistically significant in terms of acute GVHD at grade I-IV or III-IV, CMV reactivation and EBV reactivation (P>0.1).
CONCLUSION:The cell mobilization program of G-CSF combined with Plerixafor is safe and effective for being applied to allo-HSCT. The addition of Plerixafor can significantly increase the number of CD34 postive cells in the PBSC collection. Key words ; ;
